Prosecution Insights
Prosecution Insights
12 pending office actions • 6 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 5 (42%) |
| §112 only | 2 (17%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 2 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DACE DENITO, ALEXANDRA GERALDINE | 2 | 60.3% | +35.7% |
| SONG, JIANFENG | 1 | 56.2% | +33.1% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.8% |
| YU, DELPHINUS DOU YI | 1 | 50.0% | +0.0% |
| PERSONS, JENNA L | 1 | 50.0% | +60.0% |
| KONOPKA, CATHERINE ANNE | 1 | 58.2% | +64.5% |
| REGA, KYLE THOMAS | 1 | 61.8% | +40.7% |
| GIBBS, TERRA C | 1 | 63.9% | +10.4% |
| ABUZEINEH, HANAN ISAM | 1 | 56.0% | +51.4% |
| RYAN, DOUGLAS CHARLES | 1 | 40.3% | +50.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | — |
| 17638683 | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING | REGA, KYLE THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430274 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | DACE DENITO, ALEXANDRA GERALDINE | 70d |
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18746810 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | SONG, JIANFENG | — |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | — |
| 17638757 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | KONOPKA, CATHERINE ANNE | — |
| 17638683 | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING | REGA, KYLE THOMAS | — |
| 17610119 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | GIBBS, TERRA C | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1635 | 3 |
| 1633 | 2 |
| 1613 | 1 |
| 1611 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Apr 16, 2026 |
| 18746810 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | SONG, JIANFENG | 1613 | §102§112DP | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | 1611 | §102§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18474969 | ADENOSINE DEAMINASE VARIANTS AND USES THEREOF | YU, DELPHINUS DOU YI | 1636 | §112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 17638757 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | KONOPKA, CATHERINE ANNE | 1635 | DP | Final Rejection | — | Pending | Feb 25, 2022 |
| 17638683 | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING | REGA, KYLE THOMAS | 1636 | §103§112 | Final Rejection | — | Pending | Feb 25, 2022 |
| 17610119 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | GIBBS, TERRA C | 1635 | §112 | Non-Final OA | — | Pending | Nov 09, 2021 |
| 17430274 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | 70d | Pending | Aug 11, 2021 |
| 17423428 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE | ABUZEINEH, HANAN ISAM | 1633 | §103 | Final Rejection | — | Pending | Jul 15, 2021 |
| 17054348 | METHODS OF EDITING SINGLE NUCLEOTIDE POLYMORPHISM USING PROGRAMMABLE BASE EDITOR SYSTEMS | RYAN, DOUGLAS CHARLES | 1635 | §103 | Final Rejection | — | Pending | Nov 10, 2020 |
| 17054393 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Nov 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial